title: Multicenter Phase II trial of etoposide in refractory small cell lung cancer.
authors.forename: B F
authors.initials: BF
authors.lastname: Issell
authors.forename: L H
authors.initials: LH
authors.lastname: Einhorn
authors.forename: R L
authors.initials: RL
authors.lastname: Comis
authors.forename: R D
authors.initials: RD
authors.lastname: Lawson
authors.forename: L H
authors.initials: LH
authors.lastname: Baker
authors.forename: H A
authors.initials: HA
authors.lastname: Harvey
authors.forename: V A
authors.initials: VA
authors.lastname: Lanzotti
authors.forename: G L
authors.initials: GL
authors.lastname: Wampler
authors.forename: J R
authors.initials: JR
authors.lastname: Daniels
authors.forename: P N
authors.initials: PN
authors.lastname: Anderson
mesh_terms: D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D004341:Drug Evaluation; D005047:Etoposide / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D009096:Multi-Institutional Systems; D009325:Nausea / Q000139:chemically induced; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D014839:Vomiting / Q000139:chemically induced
chemical_list: D005047:Etoposide; D011034:Podophyllotoxin